A Randomized, Open-Label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma.

Trial Profile

A Randomized, Open-Label Study of the Effect of MabThera Plus Chemotherapy Versus Chemotherapy Alone on Clinical Response in Patients With Indolent Non-Hodgkin's and Mantle Cell Lymphoma.

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Jul 2015

At a glance

  • Drugs Chlorambucil; Mitoxantrone; Prednisolone; Rituximab
  • Indications Follicular lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 May 2009 Actual patients number changed from 358 to 368 as reported by ClinicalTrials.gov.
    • 09 Apr 2007 Status changed from in progress to completed.
    • 09 Apr 2007 Results published in JCO.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top